Five Prime Therapeutics to Present at Upcoming Healthcare Conference
July 31 2019 - 9:15PM
Business Wire
Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage
biotechnology company focused on discovering and developing
innovative immuno-oncology protein therapeutics today announced
that Aron Knickerbocker, Chief Executive Officer, is scheduled to
present at the following investor conference:
- The 2019 Wedbush PacGrow Healthcare Conference Wednesday,
August 14, 2019 at 8:35am ET / 5:35am PT
The presentations will be webcast and may be accessed at the
“Events & Presentations” section of the Company’s website
at:
http://investor.fiveprime.com/events.cfm. Five Prime will
maintain an archived replay of the webcast on its website for 30
days after the conference.
About Five Prime
Five Prime Therapeutics, Inc. discovers and develops innovative
protein therapeutics to improve the lives of patients with serious
diseases. Five Prime’s product candidates have innovative
mechanisms of action and address patient populations in need of
better therapies. The company focuses on researching and developing
immuno-oncology and targeted cancer therapies paired with companion
diagnostics to identify patients who are most likely to benefit
from treatment with Five Prime’s product candidates. Five Prime has
entered into strategic collaborations with leading global
pharmaceutical companies and has promising product candidates in
clinical and preclinical development. For more information, please
visit www.fiveprime.com or follow us on LinkedIn, Twitter and
Facebook.
Source: Five Prime Therapeutics, Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190731006121/en/
Media and Investor Contact Martin Forrest VP, Investor
Relations & Corporate Communications Five Prime Therapeutics,
Inc. 415-365-5625 martin.forrest@fiveprime.com
Five Prime Therapeutics (NASDAQ:FPRX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Five Prime Therapeutics (NASDAQ:FPRX)
Historical Stock Chart
From Apr 2023 to Apr 2024